BioSpace News Archive

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2019, on Tuesday, November 12, 2019 before the opening of the financial markets.

Linaclotide abstract recognized as a Presidential Poster Recipient

Athenex, Inc. announced a progress update from partner Almirall on tirbanibulin ointment for the treatment of actinic keratosis

NeoTX Therapeutics, Ltd. announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® for the treatment of advanced or metastatic solid tumors.

The first comprehensive Lab Benefit Manager, Avalon Healthcare Solutions, backed by Francisco Partners, Echo Health Ventures, and leading BlueCross BlueShield plans launches new Medical Specialty Drug Benefit Management software, which tackles the fastest growing component of healthcare costs and a leading concern for payers.

MediciNova, Inc. announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-166 for the treatment of amyotrophic lateral sclerosis

Advanced Sterilization Products announced its new brand strategy with a refreshed mission, new logo, and a redesigned website.

Vively embodies company’s mission to deliver innovative, comprehensive care to the highest risk patients managing multiple chronic conditions

Overall Data Suggest a Dose Response Relationship Across Treatment Groups

Seneca Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit to be held at the Pudong Shangri-La Hotel in East Shanghai on October 31 – November 1.